Protocols as they were published
Each entry describes what a label, registered trial or published study actually reported. Nothing here is a recommendation, and no protocol is individualised.
- Semaglutide
Semaglutide 2.4 mg weekly — approved escalation schedule
Summarise the dose-escalation schedule established by the approved prescribing label and the STEP phase 3 programme for chronic weight management.
- Evidence level
- Grade A — established in randomised phase 3 trials and reflected in an approved label
- Regulatory status
- FDA Approved for Specific Indication
Reviewed September 1, 2026View - Tirzepatide
Tirzepatide weekly — approved escalation schedule
Summarise the escalation schedule used in the SURMOUNT programme and described in approved labelling.
- Evidence level
- Grade A — phase 3 randomised trials and approved labelling
- Regulatory status
- FDA Approved for Specific Indication
Reviewed September 1, 2026View - Retatrutide (LY3437943)
Retatrutide — phase 2 trial protocol as published
Summarise the escalation and maintenance structure reported in the published phase 2 obesity trial.
- Evidence level
- Grade B — published phase 2 randomised trial; phase 3 ongoing at last review
- Regulatory status
- Clinical Trials
No established human dosing protocol exists for this compound.
Reviewed September 1, 2026View - Tesamorelin
Tesamorelin — approved daily protocol in HIV-associated lipodystrophy
Summarise the protocol established by phase 3 trials and approved labelling for reducing excess visceral abdominal fat in a defined population.
- Evidence level
- Grade A — two phase 3 randomised placebo-controlled trials and an approved label
- Regulatory status
- FDA Approved for Specific Indication
Reviewed September 1, 2026View - Bremelanotide (PT-141)
Bremelanotide — approved as-needed protocol
Summarise the as-needed administration protocol established in the RECONNECT phase 3 trials and approved labelling.
- Evidence level
- Grade A — two phase 3 randomised placebo-controlled trials and an approved label
- Regulatory status
- FDA Approved for Specific Indication
Reviewed September 1, 2026View - BPC-157
BPC-157 — research context, not a human protocol
Set out what published research does and does not establish about BPC-157 administration, and why no human protocol can responsibly be summarised.
- Evidence level
- Grade D — animal and in-vitro research; no adequate published human trials for musculoskeletal outcomes
- Regulatory status
- Not FDA Approved
No established human dosing protocol exists for this compound.
Reviewed September 1, 2026View - CJC-1295 (DAC)
CJC-1295 — phase 1 trial administration as published
Summarise how CJC-1295 was administered in the published phase 1 human research, and what those studies measured.
- Evidence level
- Grade C — phase 1 human pharmacodynamic studies of biochemical endpoints
- Regulatory status
- Not FDA Approved
No established human dosing protocol exists for this compound.
Reviewed September 1, 2026View - Thymosin alpha-1 (thymalfasin)
Thymosin alpha-1 — hepatitis B trial protocols as reported
Summarise the administration schedules reported in randomised trials and meta-analyses of chronic hepatitis B.
- Evidence level
- Grade B — randomised trials and meta-analyses with variable methodological quality
- Regulatory status
- Clinical Trials
Reviewed September 1, 2026View - Elamipretide
Elamipretide (SS-31) — clinical trial protocols as registered
Summarise the administration structure used in registered trials in primary mitochondrial myopathy and related conditions.
- Evidence level
- Grade C — randomised trials with mixed primary endpoint results
- Regulatory status
- Clinical Trials
Reviewed September 1, 2026View - GHK-Cu (copper tripeptide-1)
GHK-Cu — topical study protocols as reported
Summarise how topical GHK-Cu has been applied in published cosmetic and wound-healing studies.
- Evidence level
- Grade C — small controlled cosmetic studies plus extensive in-vitro work
- Regulatory status
- Not FDA Approved
No established human dosing protocol exists for this compound.
Reviewed September 1, 2026View - TB-500 (thymosin beta-4 fragment)
TB-500 — research context, not a human protocol
Explain what published thymosin beta-4 research covers and why no human protocol for the marketed fragment can be summarised.
- Evidence level
- Grade D — animal and in-vitro research; early human trials of a different molecule
- Regulatory status
- Research Use Only
No established human dosing protocol exists for this compound.
Reviewed September 1, 2026View - Epitalon (AEDG)
Epitalon — research context, not a human protocol
Explain the state of the Epitalon literature and why no protocol summary is defensible.
- Evidence level
- Grade E — older regional studies and animal work with minimal independent replication
- Regulatory status
- Not FDA Approved
No established human dosing protocol exists for this compound.
Reviewed September 1, 2026View